Iatrogenic immunosuppression and cutaneous malignancy.
Patients with autoimmune and inflammatory conditions often receive long-term immunosuppressive therapy. Some of the largest patient populations with iatrogenic immunosuppression include patients who have received solid-organ transplants or who have rheumatoid arthritis or psoriasis. Although treatments improve patient outcomes, individuals with immunosuppression subsequently may have an increased risk of skin cancer, including squamous cell carcinoma, basal cell carcinoma, and malignant melanoma.
Kansas City University of Medicine and Biosciences, 1750 Independence Ave, Kansas City, MO 64106, USA.
Jennifer L
JL
DePry
Kurtis B
KB
Reed
Robert H
RH
Cook-Norris
Jerry D
JD
Brewer
D002280:Basal Cell Carcinoma / Q000139:chemically induced* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000628:therapy; D005148:Facial Dermatoses / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D007049:Iatrogenic Disease / Q000453:epidemiology; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008545:Melanoma / Q000139:chemically induced* / Q000628:therapy; D016377:Organ Transplantation / Q000009:adverse effects*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000628:therapy
D007166:Immunosuppressive Agents